ABOUT US

Global Leader of Cancer Treatments

History

  • 2022
    May.

    ATB-101, Received IND Approval for Phase 3 Study

    Mar.

    Series B Round

    Jan.

    ATB-320, R&D Grant (Ministry of Trade, Industry and Energy)

  • 2021
    Aug.

    ATB-101, Phase 1 study (DDI, PK) Completed Successfully

    Feb.

    ATB-101, Received IND Approval for Phase 1 Study

    ATB-301, Received IND Approval for Phase 1 Study

    Jan.

    ATB-301, Agreement with Clinigen (UK)

  • 2020
    Dec.

    Strategic Investment with ST Pharm and 2 other Pharmaceutical Companies

    May.

    ATB-410, R&D Grant (Ministry of SMEs and Startups)

    Apr.

    ATB-301, R&D Grant (Ministry of Trade, Industry and Energy)

    Feb.

    Series A Round with Stonebridge Ventures

    Jan.

    Inno-biz Certified (Technology and Innovation-Oriented SMEs)

  • 2019
    Dec.

    Series A Round with Mega Investment & UTC Investment

    Nov.

    Immuno-oncology R&D Grant (Medical Innovation Foundation)

    Oct.

    Investment Agreement with Aju Pharm & KODIT

    Sep.

    Expansion & New Location of Pankyo R&D Center

    Jun.

    ATB-101, “K-Startup” R&D Grant (Ministry of SMEs and Startups)

    May.

    TASO CMO Agreement with ST Pharm

    Apr.

    ATB-301, Selected in “Pharm Navi” Project by MFDS (such as “Fast Track” regulation system in US FDA)

    Jan.

    ATB-101, Tech Transfer and Investment Agreement with Jeil Pharm.

  • 2018
    Sep.

    Pankyo R&D Center establishment

    Aug.

    Angel Investment

    Jul.

    Investment Agreement with TIPS

    ATB-301, R&D Grant (Ministry of SMEs and Startups)

    Feb.

    Venture Designation (Korea Technology Finance Corporation)

    Jan.

    Company Name Change (Autotelic Korea → Autotelic Bio)

  • 2017
    Sep.

    ATB-101, Government R&D Grant (Ministry of SMEs and Startups)

    Corporate R&D Center Accreditation

  • 2015
    Nov.

    Autotelic Korea Establishment